ArticleBreast cancer research and treatment2025

Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study.

Toshiaki Iwase et al.PubMed ↗Publisher ↗

No numbers read from the abstract.